Celldex Flying Solo as Pfizer Bails on CDX-110 Partnership
Though shares of Celldex Therapeutics Inc. plunged 26.2 percent on the news, President and CEO Anthony Marucci sees Pfizer Inc.'s decision to return rights to brain cancer vaccine CDX-110 (rindopepimut) as a positive event for his company. (BioWorld Today)
Step ahead of the game with the Biotech Superbook!
They say you can't know where you're going, if you don't know where you've been... BioWorld Biotech Super Book — coverage like never before! We've taken one of our most requested resources — The BioWorld State of the Industry Report — and enhanced it! The brand new 475-page report includes the deals, the projections, the R&D, the latest trends, the industry analysis, and the top drugs that surrounded our year... and shaped the future. From the bench to Wall Street to DC to Europe — The BioWorld Biotech SuperBook brings you the defining moments from the year and shows you the future from all angles. You can't afford to be without it!
Sirtris Scandal Aside, Drugs Face No Supplemental Threat
The biotech industry was abuzz last week with the news that Christoph Westphal and Michelle Dipp – who sold resveratrol-based Sirtris Pharmaceuticals Inc. to GlaxoSmithKline plc for $720 million – were exposed for selling resveratrol online. (BioWorld Perspectives)
Karo Bio Eyes 2011 Start for Eprotirome Pivotal Program
Karo Bio AB is finalizing the design of a Phase III program for its lead drug candidate, eprotirome (KB2115), which is in development for heterozygous familial hypercholesterolemia (HeFH), a genetic condition characterized by the accumulation of elevated levels of low density lipoprotein (LDL) cholesterol and increased risk of atherosclerosis at an early age. (BioWorld International)
